Update 1987 pp 135-140 | Cite as

The Role of Prostaglandins in ARDS

  • G. J. Slotman
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 3)


Biologically active metabolites of arachidonic acid have been implicated as causative agents of the Adult Respiratory Distress Syndrome (ARDS). As seen in Figure 1, arachidonic acid, generated from membrane phospholipids, is metabolized via the cyclo-oxygenase pathway to the classic prostaglandins and thromboxane A2, and via the 5-lipoxygenase pathway to the leukotrienes. Of these substances, thromboxane A2, prostacyclin, prostaglandin E2 and leukotrienes B4, C4, D4, and E4 appear to be most significant in the pathophysiology of ARDS. The purpose of this review is to summarize the current knowledge of these eicosanoids and their involvement in ARDS.


Adult Respiratory Distress Syndrome Thromboxane Synthetase Pulmonary Edema Fluid Acute Coronary Insufficiency Permeability Edema 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hock CE, Lefer AM (1985) Protective effects of a new LTD antagonist (LY-171883) in traumatic shock. Circ Shock 17:263–272PubMedGoogle Scholar
  2. 2.
    Lelcuk S, Huval WV, Valeri CR, Shepro D, Hechtman HB (1984) Inhibition of ischemia-induced thromboxane synthesis in man. J Trauma 24(5):393–396PubMedCrossRefGoogle Scholar
  3. 3.
    Slotman GJ, Quinn JV, Burchard KW, Gann DS (1984) Thromboxane interaction with cardiopulmonary dysfunction in graded bacterial sepsis. J Trauma 24(9):803–810PubMedCrossRefGoogle Scholar
  4. 4.
    Smith ME, Holcroft JW, Demling RH (1982) Prostaglandin E1 and prostacyclin infusion decrease thromboxane production in endotoxin-induced lung injury. J Surg Res 32:283–288PubMedCrossRefGoogle Scholar
  5. 5.
    Slotman GJ, Quinn JV, Burchard KW, Gann DS (1985) Thromboxane, prostacyclin, and the hemodynamic effects of graded bacteremic shock. Circ Shock 16:395–404PubMedGoogle Scholar
  6. 6.
    Slotman GJ, Burchard KW, Yellin SA, Williams JJ (1986) Prostaglandin and complement interaction in clinical acute respiratory failure. Arch Surg 121:271–274PubMedCrossRefGoogle Scholar
  7. 7.
    Slotman GJ, Yellin SA, Handy JR, Hulstyn M, Husain SE, Gann DS (1986) Thromboxane A2 mediates hemodynamic and respiratory dysfunction in graded bacteremia. Surgery 100(2):214–221PubMedGoogle Scholar
  8. 8.
    Reines HD, Cook JA, Halushka PV, Wise WC, Rambo W (1982) Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet, July 24:174–175CrossRefGoogle Scholar
  9. 9.
    Krausz MM, Utsunomiya T, Dunham AB, Valeri CR, Shepro D, Hechtman HB (1982) Inhibition of permeability edema with imidazole. Surgery 92(2):299–308PubMedGoogle Scholar
  10. 10.
    Hechtman HB, Huval WV, Mathieson MA, Stemp LI, Valeri R, Shepro D (1983) Prostaglandin and thromboxane mediation of cardiopulmonary failure. Surg Clin N Am 63(2):263–283PubMedGoogle Scholar
  11. 11.
    Slotman GJ, Burchard KW, Gann DS (1985) Thromboxane and prostacyclin in clinical acute respiratory failure. J Surg Res 39:1–7PubMedCrossRefGoogle Scholar
  12. 12.
    Leeman M, Boeynaems J-M, Degaute J-P, Vincent J-L, Kahn RJ (1985) Administration of dazoxiben, a selective thromboxane synthetase inhibitor, in the adult respiratory distress syndrome. Chest 87(6):726–730PubMedCrossRefGoogle Scholar
  13. 13.
    Reines HD, Halushka PV, Olanoff LS, et al (1985) Dazoxiben in human sepsis and adult respiratory distress syndrome. Clin Pharmacol Ther 37(4):391–395PubMedCrossRefGoogle Scholar
  14. 14.
    Huval WV, Lelcuk S, Shepro D, Hechtman HB (1984) Role of serotonin in patients with acute respiratory failure. Ann Surg 200(2):166–172PubMedCrossRefGoogle Scholar
  15. 15.
    Hammerschmidt DE, Weaver LJ, HudsonLD, Craddock PR, Jacob HS (1980) Complement-complement activation and elevated plasma C5a with adult respiratory distress syndrome. Lancet 947–949, May 3Google Scholar
  16. 16.
    Matthay MA, Eschenbacher WL, Goetzl EJ (1984) Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome. J Clin Immunol 4(6):479–484PubMedCrossRefGoogle Scholar
  17. 17.
    Bunting S, Grylglewski R, Mancada S, Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12(6):897–913PubMedCrossRefGoogle Scholar
  18. 18.
    Moncada S, Vane JR (1979) The role of prostacyclin in vascular tissue. Fed Proc 38:(1):66–71PubMedGoogle Scholar
  19. 19.
    Demling RH, Smith M, Gunther R (1981) Pulmonary injury and prostaglandin production during endotoxemia in conscious sheep. Am J Physiol 240:H348–353PubMedGoogle Scholar
  20. 20.
    Hales CA, Peterson M, King D (1981) Role of thromboxane and prostacyclin in pulmonary vasomotor changes after endotoxin in dogs. J Clin Invest 68:497–505PubMedCrossRefGoogle Scholar
  21. 21.
    Smith ME, Gunther R, Gee M, Flynn J, Demling RH (1981) Leukocytes, platelets, and thromboxane A2 in endotoxin-induced lung injury. Surgery 90(1):102–107PubMedGoogle Scholar
  22. 22.
    Borgstrum D, Slotman GJ (unpublished). Prostacyclin is sufficient alone to cause hypotension in sepsisGoogle Scholar
  23. 23.
    Hirawawa N, Ohuchi K, Sugio K, Tsurufuji S, Watanabe M, Yoshino W & S (1986) Vascular permeability responses and the role of prostaglandin E2 in an experimental allergic inflammation of air pouch type in rats. Br J Pharmacol 87:751–756Google Scholar
  24. 24.
    Ninnemann JL, Stockland AE (1984) Participation of prostaglandin E in immunosuppression following thermal injury. J Trauma 24(3):202–208CrossRefGoogle Scholar
  25. 25.
    Kunkel SL, Chensue SW, Phan SH (1986) Prostaglandins as endogenous mediators of in-terleukin 1 production. J Immunol 1136(1):186–192Google Scholar
  26. 26.
    Samuelsson B, Hammarstrom S, Murphy RC, Borgeat P (1980) Leukotrienes and slow reacting substance of anaphylaxis (SRS-A). Allergy 35:375–381PubMedCrossRefGoogle Scholar
  27. 27.
    Holroyde MC, Altounyan REC, Cole M, Dison M, Elliott EV (1981) Bronchoconstriction produced in man by Leukotrienes C and D. Lancet, July 4:17–18CrossRefGoogle Scholar
  28. 28.
    Woodward DF, Weichman BM, Gill CA, Wasserman MA (1983) The effect of synthetic leukotrienes on tracheal microvascular permeability. Prostaglandins 25(1):131–142PubMedCrossRefGoogle Scholar
  29. 29.
    Staub NC, Schultz EL, Koike K, Albertine KH (1985) Effect of neutrophil migration induced by leukotriene B4 on protein permeability in sheep lung. Fed Proc 44(1):part 1, 32–35Google Scholar
  30. 30.
    Denzlinger C, Rapp S, Hagmann W, Keppler D (1985) Leukotrienes as mediators in tissue trauma. Science, 230:330–332PubMedCrossRefGoogle Scholar
  31. 31.
    Lefer AM (1985) Eicosanoids as mediators of ischemia and shock. Fed Proc 44:275–280PubMedGoogle Scholar
  32. 32.
    Cutitar M, Yellin SA, Handy JR, Slotman GJ (unpublished) Leukotriene mediation of hypotension and respiratory failure during graded bacteremiaGoogle Scholar
  33. 33.
    Slotman GJ, Machiedo GW, Casey KF, Lyons MJ (1982) Histologic and hemodynamic effects of prostacyclin and prostaglandin E1 following oleic acid infusion. Surgery 92(1):93–100PubMedGoogle Scholar
  34. 34.
    Steinberg SM, Dehring DJ, Gower WR, Vento JM, Lowery DB, Cloutier CT (1983) Prostacyclin in experimental septic acute respiratory failure. J Surg Res 34:298–302PubMedCrossRefGoogle Scholar
  35. 35.
    Slotman GJ, D’Arezzo A, Gann DS (submitted) Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J TraumaGoogle Scholar
  36. 36.
    Kazui T, Webb WR, Wax SD (1976) Effect of prostaglandin E1 on the lung in hemorrhagic shock. Surgical Forum 187–189Google Scholar
  37. 37.
    Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE (1982) Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 66(2):334–338PubMedCrossRefGoogle Scholar
  38. 38.
    Szczeklik A, Szczeklik J, Nizankowski R, Gluszko P (1980) Prostacyclin for acute coronary insufficiency. Artery 8(1):7–11PubMedGoogle Scholar
  39. 39.
    Chelly J, Fabiani J-N, Chahine R, Tricot A-M, Carpentier A, Passelecq J, Dubost C (1982) Hemodynamic and metabolic effects of prostacyclin after coronary bypass surgery. Circulation 66(suppl 1):I 45–I 49Google Scholar
  40. 40.
    Holcroft JW, Vassar MJ, Weber CJ (1986) Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. Ann Surg 203(4):371–378PubMedCrossRefGoogle Scholar
  41. 41.
    Lelcuk S, Huvan WV, Valeri CR, Shepro D, Hechtman HB (1984) Inhibition of ischemia-induced thromboxane synthesis in man. J Trauma 24(5):393–395PubMedCrossRefGoogle Scholar
  42. 42.
    Beetens JR, Loots W, Somers Y, Coene MC, DeClerck F (1986) Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo. Biochem Pharmac 35(6):883–891CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • G. J. Slotman

There are no affiliations available

Personalised recommendations